WELLESLEY HILLS, Mass., Feb. 8 /PRNewswire-FirstCall/ -- MacroChem's President and CEO, Robert DeLuccia, will present at the BIO CEO & Investor Conference on Wednesday, February 14th at 2:15pm EST at The Waldorf Astoria Hotel in New York, NY.
A live audio webcast of this presentation can be accessed via: http://www.corporateir.net/ireye/conflobby.zhtml?ticker=MACM&item_id=1467830. Some information about MacroChem and an audio replay of the presentation will also be available for 90 days after the conference.
About MacroChem
MacroChem Corporation is a specialty pharmaceutical company with two clinical development stage products containing our patented enhancer, SEPA(R): EcoNail(TM), to treat fungal infection of the nail and Opterone(R), to treat male hypogonadism. In addition to our SEPA technology, we are also evaluating applications for MacroDerm(TM), our patented series of polymers that impede penetration of active ingredients through the skin. For more information visit our website, http://www.macrochem.com.
About BIO CEO Conference
The 9th Annual BIO CEO & Investor Conference will provide a neutral forum where senior biotechnology executives, institutional investors, industry analysts, venture capitalists, investment bankers and other industry experts will have the opportunity to shape the future investment landscape of the biotechnology industry. Hosted by the Biotechnology Industry Organization (BIO), the largest industry organization focused exclusively on biotechnology, the BIO CEO & Investor Conference will feature issue-oriented plenary sessions, educational sessions focused on hot technologies, therapeutics and key business issues, company presentations, one-on-one meetings, and networking opportunities.
Forward-Looking Statements
With the exception of historical information contained in this press release, the matters described herein are forward-looking statements that involve risks and uncertainties. MacroChem's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed or referred to in the section entitled "Risk Factors" in MacroChem's Annual Report on Form 10-K, as well as those discussed elsewhere therein, and include, without limitation, risks regarding product development, the timing and results of clinical trials, the regulatory approval process, capital requirements, financial condition, patent protection and dependence on third parties for development and licensing arrangements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. MacroChem undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For more information visit our website, http://www.macrochem.com.
Contact: MacroChem Corp.: Bernard Patriacca - VP/CFO (781) 489-7310 Investor Relations: The Investor Relations Group, Inc. Jordan Silverstein/Christine Berni (212) 825-3210
MacroChem CorporationCONTACT: Bernard Patriacca, VP-CFO of MacroChem Corporation,+1-781-489-7310; or Investor Relations, Jordan Silverstein, or ChristineBerni, of The Investor Relations Group, Inc., +1-212-825-3210
Web site: http://www.macrochem.com/
